JP7840054B2 - 神経細胞変性阻害剤 - Google Patents

神経細胞変性阻害剤

Info

Publication number
JP7840054B2
JP7840054B2 JP2022510782A JP2022510782A JP7840054B2 JP 7840054 B2 JP7840054 B2 JP 7840054B2 JP 2022510782 A JP2022510782 A JP 2022510782A JP 2022510782 A JP2022510782 A JP 2022510782A JP 7840054 B2 JP7840054 B2 JP 7840054B2
Authority
JP
Japan
Prior art keywords
methyl
triazine
phenyl
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022510782A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021193982A5 (https=
JPWO2021193982A1 (https=
Inventor
治久 井上
恵子 今村
誠 古澤
雅昭 船田
哲 林
圭佑 今村
貴裕 杉本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JPWO2021193982A1 publication Critical patent/JPWO2021193982A1/ja
Publication of JPWO2021193982A5 publication Critical patent/JPWO2021193982A5/ja
Application granted granted Critical
Publication of JP7840054B2 publication Critical patent/JP7840054B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022510782A 2020-03-27 2021-03-26 神経細胞変性阻害剤 Active JP7840054B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020058414 2020-03-27
JP2020058414 2020-03-27
PCT/JP2021/014251 WO2021193982A1 (ja) 2020-03-27 2021-03-26 神経細胞変性阻害剤

Publications (3)

Publication Number Publication Date
JPWO2021193982A1 JPWO2021193982A1 (https=) 2021-09-30
JPWO2021193982A5 JPWO2021193982A5 (https=) 2024-08-02
JP7840054B2 true JP7840054B2 (ja) 2026-04-03

Family

ID=77892307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510782A Active JP7840054B2 (ja) 2020-03-27 2021-03-26 神経細胞変性阻害剤

Country Status (6)

Country Link
US (1) US20230120205A1 (https=)
EP (1) EP4129293A4 (https=)
JP (1) JP7840054B2 (https=)
CN (1) CN115335058B (https=)
CA (1) CA3172328A1 (https=)
WO (1) WO2021193982A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502956A (ja) 2007-04-24 2011-01-27 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
WO2013026874A1 (en) 2011-08-22 2013-02-28 Lead Discovery Center Gmbh Cdk9 inhibitors in the treatment of midline carcinoma
JP2014515363A (ja) 2011-05-24 2014-06-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング スルホキシミン基を含有する４−アリール−ｎ−フェニル−１，３，５−トリアジン−２−アミン
WO2019067587A1 (en) 2017-09-26 2019-04-04 University Of Florida Research Foundation, Incorporated USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS
WO2019217757A1 (en) 2018-05-09 2019-11-14 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
ZA200709038B (en) * 2005-04-13 2009-01-28 Neuraxon Inc Substituted indole compounds having nos inhibitory activity
EP2137164B1 (en) * 2007-04-24 2015-08-26 AstraZeneca AB Inhibitors of protein kinases
EP2137163B1 (en) * 2007-04-24 2015-03-18 AstraZeneca AB Inhibitors of protein kinases
ES2579949T3 (es) * 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
US20130079345A1 (en) * 2010-03-22 2013-03-28 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
JP6473077B2 (ja) 2013-03-21 2019-02-20 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
CN107530430A (zh) * 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
CN105085427B (zh) * 2015-08-21 2018-06-05 中国科学院广州生物医药与健康研究院 一类苯并[d]异恶唑类化合物及其应用
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
CN107304189A (zh) * 2016-04-18 2017-10-31 北京大学 一种三嗪化合物及其制备方法和应用
JP6959632B2 (ja) 2017-05-15 2021-11-02 学校法人近畿大学 筋萎縮性側索硬化症又は前頭側頭型認知症の予防又は治療剤
CN110582491B (zh) * 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7135692B2 (ja) 2018-10-05 2022-09-13 ニプロ株式会社 排液システム

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502956A (ja) 2007-04-24 2011-01-27 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
JP2014515363A (ja) 2011-05-24 2014-06-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング スルホキシミン基を含有する４−アリール−ｎ−フェニル−１，３，５−トリアジン−２−アミン
WO2013026874A1 (en) 2011-08-22 2013-02-28 Lead Discovery Center Gmbh Cdk9 inhibitors in the treatment of midline carcinoma
WO2019067587A1 (en) 2017-09-26 2019-04-04 University Of Florida Research Foundation, Incorporated USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS
WO2019217757A1 (en) 2018-05-09 2019-11-14 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ChemMedChem，2017年，Volume.12, Issue.21，pp.1776-1793
Human Molecular Genetics，2017年，Volume.26, Issue.17，pp.3421-3431
Journal of Molecular Neuroscience，2020年03月13日，Volume.70，pp.1140-1152
Medical Hypotheses，2005年，Volume.64, Issue.1，pp.120-123

Also Published As

Publication number Publication date
US20230120205A1 (en) 2023-04-20
EP4129293A4 (en) 2024-04-03
CN115335058A (zh) 2022-11-11
CA3172328A1 (en) 2021-09-30
EP4129293A1 (en) 2023-02-08
JPWO2021193982A1 (https=) 2021-09-30
CN115335058B (zh) 2024-12-06
WO2021193982A1 (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2015279047B2 (en) Aryl receptor modulators and methods of making and using the same
JP6856900B2 (ja) トール様受容体７またはトール様受容体９の活性化阻害剤
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP4880031B2 (ja) 全般性不安障害の処置に用いる医薬を製造するためのアゴメラチンの使用
IL279755B1 (en) Senolytic compositions and uses thereof
WO2020086728A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
US20230059136A1 (en) The compounds and compositions for treating conditions associated with nlrp activity
WO2019149286A1 (en) Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
JP5810099B2 (ja) ５−ｈｔ（２ｂ）受容体でアンタゴニスト活性を有する高選択性５−ｈｔ（２ｃ）受容体アゴニスト
JP7840054B2 (ja) 神経細胞変性阻害剤
CA3237988A1 (en) Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
WO2016049595A1 (en) Heteroaryl inhibitors of pde4
HK40082876A (en) Nerve cell degeneration inhibitor
WO2015163431A1 (ja) 片頭痛治療剤
CN118765274A (zh) 用于治疗动脉粥样硬化及相关疾病的alpha蛋白激酶1抑制剂
JP7618237B2 (ja) 運動神経細胞変性阻害剤
JP2011088919A (ja) アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
WO2019044940A1 (ja) 環状アミン誘導体及びその医薬用途
WO2023067388A1 (en) Uses of cftr modulator and/or pde4 inhibitor compounds
CN117777102A (zh) 一种btk抑制剂及其制备方法与应用
RU2667954C2 (ru) Фармацевтическая композиция для лечения функциональных психических расстройств
JP2000351782A (ja) メタボトロピックグルタメート受容体作用薬及び新規チアゾロベンゾイミダゾール誘導体
TW202214585A (zh) 經取代之異喹啉基甲基醯胺類、其類似物及使用其之方法
HK40073574B (zh) 以稠合嘧啶化合物为有效成分的治疗剂

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260316

R150 Certificate of patent or registration of utility model

Ref document number: 7840054

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150